Avenge Bio

Also Clin0 lung cancers; AVB-002 Clin0 multiple cancers; AVB-003 RD undisclosed; 2 undisclosed programs RD undisclosed

Avenge Bio is developing immunotherapies to eradicate intractable solid tumors. Building an effective immune response is one strategy to eliminate cancer cells. Avenge’s approach to attain this involves their proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines. Cytokines generate a robust, local and systemic anti-tumor immune response, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform identifies potent immune effector molecules that can be used for localized modulation of the immune system. Avenge’s lead candidate, ABV-001, is an encapsulated cell product engineered to produce the cytokine IL-2 and is in clinical trials for patients with serous adenocarcinoma.

Jobs: